Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Enzalutamide treatment for the whole spectrum of CRPC

Nature Reviews Urology volume 15, pages 663–665 (2018)Cite this article

Subjects

The FDA recently expanded the indication for enzalutamide for the treatment of all men with metastatic and nonmetastatic castration-resistant prostate cancer on the basis of the PROSPER trial. Now that both disease states can have the same treatment, the need to thoroughly identify metastatic lesions is questioned.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Current and potential metastatic work-ups for men with castration-resistant prostate cancer.

References

  1. Hussain, M. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 378, 2465–2474 (2018).

    Article  CAS  Google Scholar 

  2. Smith, M. R. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 378, 1408–1418 (2018).

    Article  CAS  Google Scholar 

  3. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).

    Article  CAS  Google Scholar 

  4. Beer, T. M. & Tombal, B. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 1755–1756 (2014).

    Article  Google Scholar 

  5. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

    Article  CAS  Google Scholar 

  6. Chandler, R. & de Bono, J. Second-generation antiandrogens in nonmetastatic CRPC. Nat. Rev. Urol. 15, 342–344 (2018).

    Article  CAS  Google Scholar 

  7. Gomella, L. G. Prostate cancer CRPC stage M0 and M1: do we need stage M0.5? Can. J. Urol. 25, 9220 (2018).

    PubMed  Google Scholar 

  8. Li, R. et al. The use of PET/CT in prostate cancer. Prostate Cancer Prostat. Dis. 21, 4–21 (2018).

    Article  Google Scholar 

  9. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/record/NCT02319837 (2018).

  10. Whitney, C. et al. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. (in the press).

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Hanson Zhao & Stephen Freedland

  2. Section of Urology, Durham VA Medical Center, Durham, NC, USA

    Stephen Freedland

Authors
  1. Hanson Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Freedland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen Freedland.

Ethics declarations

Competing interests

S.F. is a consultant to Pfizer, Astellas, and Janssen. H.Z. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, H., Freedland, S. Enzalutamide treatment for the whole spectrum of CRPC. Nat Rev Urol 15, 663–665 (2018). https://doi.org/10.1038/s41585-018-0090-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-018-0090-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer